Home Healthcare Pharmaceuticals Neurodegenerative Disease Market

Neurodegenerative Disease Market Size, Share & Trends Analysis Report By Disease Indication (Multiple Sclerosis, Parkinson's Disease, Alzheimer's Disease, Others), By Drug Type (Immunomodulator, Vesicular Monoamine Transporter 2 (VMAT2), Others), By Routes of Administration (Oral, Intravenous (IV) delivery, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: December 10, 2025 | Author: Debashree B | Format: | Report Code: SR1496DR | Pages: 110
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Neurodegenerative Disease Market, By Disease Indication 2022-2034 (USD MILLION/ Units)
    1. Multiple Sclerosis
    2. Parkinson's Disease
    3. Alzheimer's Disease
    4. Others
  2. Neurodegenerative Disease Market, By Drug Type 2022-2034 (USD MILLION/ Units)
    1. Immunomodulator
    2. Vesicular Monoamine Transporter 2 (VMAT2)
    3. Others
  3. Neurodegenerative Disease Market, By Routes of Administration 2022-2034 (USD MILLION/ Units)
    1. Oral
    2. Intravenous (IV) delivery
    3. Others
  4. Regional Neurodegenerative Disease Market
    1. North America
      1. North America Neurodegenerative Disease Market By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
      2. North America Neurodegenerative Disease Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Immunomodulator
        2. Vesicular Monoamine Transporter 2 (VMAT2)
        3. Others
      3. North America Neurodegenerative Disease Market By Routes of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Intravenous (IV) delivery
        3. Others
      4. U.S. Neurodegenerative Disease Market
        1. U.S. Neurodegenerative Disease Market By Disease Indication 2022-2034 (USD MILLION/ Units)
          1. Multiple Sclerosis
          2. Parkinson's Disease
          3. Alzheimer's Disease
          4. Others
        2. U.S. Neurodegenerative Disease Market By Drug Type 2022-2034 (USD MILLION/ Units)
          1. Immunomodulator
          2. Vesicular Monoamine Transporter 2 (VMAT2)
          3. Others
        3. U.S. Neurodegenerative Disease Market By Routes of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Intravenous (IV) delivery
          3. Others
      5. Canada Neurodegenerative Disease Market
        1. Canada Neurodegenerative Disease Market By Disease Indication 2022-2034 (USD MILLION/ Units)
          1. Multiple Sclerosis
          2. Parkinson's Disease
          3. Alzheimer's Disease
          4. Others
        2. Canada Neurodegenerative Disease Market By Drug Type 2022-2034 (USD MILLION/ Units)
          1. Immunomodulator
          2. Vesicular Monoamine Transporter 2 (VMAT2)
          3. Others
        3. Canada Neurodegenerative Disease Market By Routes of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Intravenous (IV) delivery
          3. Others
    2. Europe
      1. Europe Neurodegenerative Disease Market By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
      2. Europe Neurodegenerative Disease Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Immunomodulator
        2. Vesicular Monoamine Transporter 2 (VMAT2)
        3. Others
      3. Europe Neurodegenerative Disease Market By Routes of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Intravenous (IV) delivery
        3. Others
      4. U.K. Neurodegenerative Disease Market
        1. U.K. Neurodegenerative Disease Market By Disease Indication 2022-2034 (USD MILLION/ Units)
          1. Multiple Sclerosis
          2. Parkinson's Disease
          3. Alzheimer's Disease
          4. Others
        2. U.K. Neurodegenerative Disease Market By Drug Type 2022-2034 (USD MILLION/ Units)
          1. Immunomodulator
          2. Vesicular Monoamine Transporter 2 (VMAT2)
          3. Others
        3. U.K. Neurodegenerative Disease Market By Routes of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Intravenous (IV) delivery
          3. Others
      5. Germany Neurodegenerative Disease Market
        1. Germany Neurodegenerative Disease Market By Disease Indication 2022-2034 (USD MILLION/ Units)
          1. Multiple Sclerosis
          2. Parkinson's Disease
          3. Alzheimer's Disease
          4. Others
        2. Germany Neurodegenerative Disease Market By Drug Type 2022-2034 (USD MILLION/ Units)
          1. Immunomodulator
          2. Vesicular Monoamine Transporter 2 (VMAT2)
          3. Others
        3. Germany Neurodegenerative Disease Market By Routes of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Intravenous (IV) delivery
          3. Others
      6. France Neurodegenerative Disease Market
        1. France Neurodegenerative Disease Market By Disease Indication 2022-2034 (USD MILLION/ Units)
          1. Multiple Sclerosis
          2. Parkinson's Disease
          3. Alzheimer's Disease
          4. Others
        2. France Neurodegenerative Disease Market By Drug Type 2022-2034 (USD MILLION/ Units)
          1. Immunomodulator
          2. Vesicular Monoamine Transporter 2 (VMAT2)
          3. Others
        3. France Neurodegenerative Disease Market By Routes of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Intravenous (IV) delivery
          3. Others
      7. Spain Neurodegenerative Disease Market
        1. Spain Neurodegenerative Disease Market By Disease Indication 2022-2034 (USD MILLION/ Units)
          1. Multiple Sclerosis
          2. Parkinson's Disease
          3. Alzheimer's Disease
          4. Others
        2. Spain Neurodegenerative Disease Market By Drug Type 2022-2034 (USD MILLION/ Units)
          1. Immunomodulator
          2. Vesicular Monoamine Transporter 2 (VMAT2)
          3. Others
        3. Spain Neurodegenerative Disease Market By Routes of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Intravenous (IV) delivery
          3. Others
      8. Italy Neurodegenerative Disease Market
        1. Italy Neurodegenerative Disease Market By Disease Indication 2022-2034 (USD MILLION/ Units)
          1. Multiple Sclerosis
          2. Parkinson's Disease
          3. Alzheimer's Disease
          4. Others
        2. Italy Neurodegenerative Disease Market By Drug Type 2022-2034 (USD MILLION/ Units)
          1. Immunomodulator
          2. Vesicular Monoamine Transporter 2 (VMAT2)
          3. Others
        3. Italy Neurodegenerative Disease Market By Routes of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Intravenous (IV) delivery
          3. Others
      9. Russia Neurodegenerative Disease Market
        1. Russia Neurodegenerative Disease Market By Disease Indication 2022-2034 (USD MILLION/ Units)
          1. Multiple Sclerosis
          2. Parkinson's Disease
          3. Alzheimer's Disease
          4. Others
        2. Russia Neurodegenerative Disease Market By Drug Type 2022-2034 (USD MILLION/ Units)
          1. Immunomodulator
          2. Vesicular Monoamine Transporter 2 (VMAT2)
          3. Others
        3. Russia Neurodegenerative Disease Market By Routes of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Intravenous (IV) delivery
          3. Others
      10. Nordic Neurodegenerative Disease Market
        1. Nordic Neurodegenerative Disease Market By Disease Indication 2022-2034 (USD MILLION/ Units)
          1. Multiple Sclerosis
          2. Parkinson's Disease
          3. Alzheimer's Disease
          4. Others
        2. Nordic Neurodegenerative Disease Market By Drug Type 2022-2034 (USD MILLION/ Units)
          1. Immunomodulator
          2. Vesicular Monoamine Transporter 2 (VMAT2)
          3. Others
        3. Nordic Neurodegenerative Disease Market By Routes of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Intravenous (IV) delivery
          3. Others
      11. Benelux Neurodegenerative Disease Market
        1. Benelux Neurodegenerative Disease Market By Disease Indication 2022-2034 (USD MILLION/ Units)
          1. Multiple Sclerosis
          2. Parkinson's Disease
          3. Alzheimer's Disease
          4. Others
        2. Benelux Neurodegenerative Disease Market By Drug Type 2022-2034 (USD MILLION/ Units)
          1. Immunomodulator
          2. Vesicular Monoamine Transporter 2 (VMAT2)
          3. Others
        3. Benelux Neurodegenerative Disease Market By Routes of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Intravenous (IV) delivery
          3. Others
      12. Rest of Europe Neurodegenerative Disease Market
        1. Rest of Europe Neurodegenerative Disease Market By Disease Indication 2022-2034 (USD MILLION/ Units)
          1. Multiple Sclerosis
          2. Parkinson's Disease
          3. Alzheimer's Disease
          4. Others
        2. Rest of Europe Neurodegenerative Disease Market By Drug Type 2022-2034 (USD MILLION/ Units)
          1. Immunomodulator
          2. Vesicular Monoamine Transporter 2 (VMAT2)
          3. Others
        3. Rest of Europe Neurodegenerative Disease Market By Routes of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Intravenous (IV) delivery
          3. Others
    3. APAC
      1. APAC Neurodegenerative Disease Market By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
      2. APAC Neurodegenerative Disease Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Immunomodulator
        2. Vesicular Monoamine Transporter 2 (VMAT2)
        3. Others
      3. APAC Neurodegenerative Disease Market By Routes of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Intravenous (IV) delivery
        3. Others
      4. China Neurodegenerative Disease Market
        1. China Neurodegenerative Disease Market By Disease Indication 2022-2034 (USD MILLION/ Units)
          1. Multiple Sclerosis
          2. Parkinson's Disease
          3. Alzheimer's Disease
          4. Others
        2. China Neurodegenerative Disease Market By Drug Type 2022-2034 (USD MILLION/ Units)
          1. Immunomodulator
          2. Vesicular Monoamine Transporter 2 (VMAT2)
          3. Others
        3. China Neurodegenerative Disease Market By Routes of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Intravenous (IV) delivery
          3. Others
      5. Korea Neurodegenerative Disease Market
        1. Korea Neurodegenerative Disease Market By Disease Indication 2022-2034 (USD MILLION/ Units)
          1. Multiple Sclerosis
          2. Parkinson's Disease
          3. Alzheimer's Disease
          4. Others
        2. Korea Neurodegenerative Disease Market By Drug Type 2022-2034 (USD MILLION/ Units)
          1. Immunomodulator
          2. Vesicular Monoamine Transporter 2 (VMAT2)
          3. Others
        3. Korea Neurodegenerative Disease Market By Routes of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Intravenous (IV) delivery
          3. Others
      6. Japan Neurodegenerative Disease Market
        1. Japan Neurodegenerative Disease Market By Disease Indication 2022-2034 (USD MILLION/ Units)
          1. Multiple Sclerosis
          2. Parkinson's Disease
          3. Alzheimer's Disease
          4. Others
        2. Japan Neurodegenerative Disease Market By Drug Type 2022-2034 (USD MILLION/ Units)
          1. Immunomodulator
          2. Vesicular Monoamine Transporter 2 (VMAT2)
          3. Others
        3. Japan Neurodegenerative Disease Market By Routes of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Intravenous (IV) delivery
          3. Others
      7. India Neurodegenerative Disease Market
        1. India Neurodegenerative Disease Market By Disease Indication 2022-2034 (USD MILLION/ Units)
          1. Multiple Sclerosis
          2. Parkinson's Disease
          3. Alzheimer's Disease
          4. Others
        2. India Neurodegenerative Disease Market By Drug Type 2022-2034 (USD MILLION/ Units)
          1. Immunomodulator
          2. Vesicular Monoamine Transporter 2 (VMAT2)
          3. Others
        3. India Neurodegenerative Disease Market By Routes of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Intravenous (IV) delivery
          3. Others
      8. Australia Neurodegenerative Disease Market
        1. Australia Neurodegenerative Disease Market By Disease Indication 2022-2034 (USD MILLION/ Units)
          1. Multiple Sclerosis
          2. Parkinson's Disease
          3. Alzheimer's Disease
          4. Others
        2. Australia Neurodegenerative Disease Market By Drug Type 2022-2034 (USD MILLION/ Units)
          1. Immunomodulator
          2. Vesicular Monoamine Transporter 2 (VMAT2)
          3. Others
        3. Australia Neurodegenerative Disease Market By Routes of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Intravenous (IV) delivery
          3. Others
      9. Taiwan Neurodegenerative Disease Market
        1. Taiwan Neurodegenerative Disease Market By Disease Indication 2022-2034 (USD MILLION/ Units)
          1. Multiple Sclerosis
          2. Parkinson's Disease
          3. Alzheimer's Disease
          4. Others
        2. Taiwan Neurodegenerative Disease Market By Drug Type 2022-2034 (USD MILLION/ Units)
          1. Immunomodulator
          2. Vesicular Monoamine Transporter 2 (VMAT2)
          3. Others
        3. Taiwan Neurodegenerative Disease Market By Routes of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Intravenous (IV) delivery
          3. Others
      10. South East Asia Neurodegenerative Disease Market
        1. South East Asia Neurodegenerative Disease Market By Disease Indication 2022-2034 (USD MILLION/ Units)
          1. Multiple Sclerosis
          2. Parkinson's Disease
          3. Alzheimer's Disease
          4. Others
        2. South East Asia Neurodegenerative Disease Market By Drug Type 2022-2034 (USD MILLION/ Units)
          1. Immunomodulator
          2. Vesicular Monoamine Transporter 2 (VMAT2)
          3. Others
        3. South East Asia Neurodegenerative Disease Market By Routes of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Intravenous (IV) delivery
          3. Others
      11. Rest of Asia-Pacific Neurodegenerative Disease Market
        1. Rest of Asia-Pacific Neurodegenerative Disease Market By Disease Indication 2022-2034 (USD MILLION/ Units)
          1. Multiple Sclerosis
          2. Parkinson's Disease
          3. Alzheimer's Disease
          4. Others
        2. Rest of Asia-Pacific Neurodegenerative Disease Market By Drug Type 2022-2034 (USD MILLION/ Units)
          1. Immunomodulator
          2. Vesicular Monoamine Transporter 2 (VMAT2)
          3. Others
        3. Rest of Asia-Pacific Neurodegenerative Disease Market By Routes of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Intravenous (IV) delivery
          3. Others
    4. Middle East and Africa
      1. Middle East and Africa Neurodegenerative Disease Market By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
      2. Middle East and Africa Neurodegenerative Disease Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Immunomodulator
        2. Vesicular Monoamine Transporter 2 (VMAT2)
        3. Others
      3. Middle East and Africa Neurodegenerative Disease Market By Routes of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Intravenous (IV) delivery
        3. Others
      4. UAE Neurodegenerative Disease Market
        1. UAE Neurodegenerative Disease Market By Disease Indication 2022-2034 (USD MILLION/ Units)
          1. Multiple Sclerosis
          2. Parkinson's Disease
          3. Alzheimer's Disease
          4. Others
        2. UAE Neurodegenerative Disease Market By Drug Type 2022-2034 (USD MILLION/ Units)
          1. Immunomodulator
          2. Vesicular Monoamine Transporter 2 (VMAT2)
          3. Others
        3. UAE Neurodegenerative Disease Market By Routes of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Intravenous (IV) delivery
          3. Others
      5. Turkey Neurodegenerative Disease Market
        1. Turkey Neurodegenerative Disease Market By Disease Indication 2022-2034 (USD MILLION/ Units)
          1. Multiple Sclerosis
          2. Parkinson's Disease
          3. Alzheimer's Disease
          4. Others
        2. Turkey Neurodegenerative Disease Market By Drug Type 2022-2034 (USD MILLION/ Units)
          1. Immunomodulator
          2. Vesicular Monoamine Transporter 2 (VMAT2)
          3. Others
        3. Turkey Neurodegenerative Disease Market By Routes of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Intravenous (IV) delivery
          3. Others
      6. Saudi Arabia Neurodegenerative Disease Market
        1. Saudi Arabia Neurodegenerative Disease Market By Disease Indication 2022-2034 (USD MILLION/ Units)
          1. Multiple Sclerosis
          2. Parkinson's Disease
          3. Alzheimer's Disease
          4. Others
        2. Saudi Arabia Neurodegenerative Disease Market By Drug Type 2022-2034 (USD MILLION/ Units)
          1. Immunomodulator
          2. Vesicular Monoamine Transporter 2 (VMAT2)
          3. Others
        3. Saudi Arabia Neurodegenerative Disease Market By Routes of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Intravenous (IV) delivery
          3. Others
      7. South Africa Neurodegenerative Disease Market
        1. South Africa Neurodegenerative Disease Market By Disease Indication 2022-2034 (USD MILLION/ Units)
          1. Multiple Sclerosis
          2. Parkinson's Disease
          3. Alzheimer's Disease
          4. Others
        2. South Africa Neurodegenerative Disease Market By Drug Type 2022-2034 (USD MILLION/ Units)
          1. Immunomodulator
          2. Vesicular Monoamine Transporter 2 (VMAT2)
          3. Others
        3. South Africa Neurodegenerative Disease Market By Routes of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Intravenous (IV) delivery
          3. Others
      8. Egypt Neurodegenerative Disease Market
        1. Egypt Neurodegenerative Disease Market By Disease Indication 2022-2034 (USD MILLION/ Units)
          1. Multiple Sclerosis
          2. Parkinson's Disease
          3. Alzheimer's Disease
          4. Others
        2. Egypt Neurodegenerative Disease Market By Drug Type 2022-2034 (USD MILLION/ Units)
          1. Immunomodulator
          2. Vesicular Monoamine Transporter 2 (VMAT2)
          3. Others
        3. Egypt Neurodegenerative Disease Market By Routes of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Intravenous (IV) delivery
          3. Others
      9. Nigeria Neurodegenerative Disease Market
        1. Nigeria Neurodegenerative Disease Market By Disease Indication 2022-2034 (USD MILLION/ Units)
          1. Multiple Sclerosis
          2. Parkinson's Disease
          3. Alzheimer's Disease
          4. Others
        2. Nigeria Neurodegenerative Disease Market By Drug Type 2022-2034 (USD MILLION/ Units)
          1. Immunomodulator
          2. Vesicular Monoamine Transporter 2 (VMAT2)
          3. Others
        3. Nigeria Neurodegenerative Disease Market By Routes of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Intravenous (IV) delivery
          3. Others
      10. Rest of MEA Neurodegenerative Disease Market
        1. Rest of MEA Neurodegenerative Disease Market By Disease Indication 2022-2034 (USD MILLION/ Units)
          1. Multiple Sclerosis
          2. Parkinson's Disease
          3. Alzheimer's Disease
          4. Others
        2. Rest of MEA Neurodegenerative Disease Market By Drug Type 2022-2034 (USD MILLION/ Units)
          1. Immunomodulator
          2. Vesicular Monoamine Transporter 2 (VMAT2)
          3. Others
        3. Rest of MEA Neurodegenerative Disease Market By Routes of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Intravenous (IV) delivery
          3. Others
    5. LATAM
      1. LATAM Neurodegenerative Disease Market By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
      2. LATAM Neurodegenerative Disease Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Immunomodulator
        2. Vesicular Monoamine Transporter 2 (VMAT2)
        3. Others
      3. LATAM Neurodegenerative Disease Market By Routes of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Intravenous (IV) delivery
        3. Others
      4. Brazil Neurodegenerative Disease Market
        1. Brazil Neurodegenerative Disease Market By Disease Indication 2022-2034 (USD MILLION/ Units)
          1. Multiple Sclerosis
          2. Parkinson's Disease
          3. Alzheimer's Disease
          4. Others
        2. Brazil Neurodegenerative Disease Market By Drug Type 2022-2034 (USD MILLION/ Units)
          1. Immunomodulator
          2. Vesicular Monoamine Transporter 2 (VMAT2)
          3. Others
        3. Brazil Neurodegenerative Disease Market By Routes of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Intravenous (IV) delivery
          3. Others
      5. Mexico Neurodegenerative Disease Market
        1. Mexico Neurodegenerative Disease Market By Disease Indication 2022-2034 (USD MILLION/ Units)
          1. Multiple Sclerosis
          2. Parkinson's Disease
          3. Alzheimer's Disease
          4. Others
        2. Mexico Neurodegenerative Disease Market By Drug Type 2022-2034 (USD MILLION/ Units)
          1. Immunomodulator
          2. Vesicular Monoamine Transporter 2 (VMAT2)
          3. Others
        3. Mexico Neurodegenerative Disease Market By Routes of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Intravenous (IV) delivery
          3. Others
      6. Argentina Neurodegenerative Disease Market
        1. Argentina Neurodegenerative Disease Market By Disease Indication 2022-2034 (USD MILLION/ Units)
          1. Multiple Sclerosis
          2. Parkinson's Disease
          3. Alzheimer's Disease
          4. Others
        2. Argentina Neurodegenerative Disease Market By Drug Type 2022-2034 (USD MILLION/ Units)
          1. Immunomodulator
          2. Vesicular Monoamine Transporter 2 (VMAT2)
          3. Others
        3. Argentina Neurodegenerative Disease Market By Routes of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Intravenous (IV) delivery
          3. Others
      7. Chile Neurodegenerative Disease Market
        1. Chile Neurodegenerative Disease Market By Disease Indication 2022-2034 (USD MILLION/ Units)
          1. Multiple Sclerosis
          2. Parkinson's Disease
          3. Alzheimer's Disease
          4. Others
        2. Chile Neurodegenerative Disease Market By Drug Type 2022-2034 (USD MILLION/ Units)
          1. Immunomodulator
          2. Vesicular Monoamine Transporter 2 (VMAT2)
          3. Others
        3. Chile Neurodegenerative Disease Market By Routes of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Intravenous (IV) delivery
          3. Others
      8. Colombia Neurodegenerative Disease Market
        1. Colombia Neurodegenerative Disease Market By Disease Indication 2022-2034 (USD MILLION/ Units)
          1. Multiple Sclerosis
          2. Parkinson's Disease
          3. Alzheimer's Disease
          4. Others
        2. Colombia Neurodegenerative Disease Market By Drug Type 2022-2034 (USD MILLION/ Units)
          1. Immunomodulator
          2. Vesicular Monoamine Transporter 2 (VMAT2)
          3. Others
        3. Colombia Neurodegenerative Disease Market By Routes of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Intravenous (IV) delivery
          3. Others
      9. Rest of LATAM Neurodegenerative Disease Market
        1. Rest of LATAM Neurodegenerative Disease Market By Disease Indication 2022-2034 (USD MILLION/ Units)
          1. Multiple Sclerosis
          2. Parkinson's Disease
          3. Alzheimer's Disease
          4. Others
        2. Rest of LATAM Neurodegenerative Disease Market By Drug Type 2022-2034 (USD MILLION/ Units)
          1. Immunomodulator
          2. Vesicular Monoamine Transporter 2 (VMAT2)
          3. Others
        3. Rest of LATAM Neurodegenerative Disease Market By Routes of Administration 2022-2034 (USD MILLION/ Units)
          1. Oral
          2. Intravenous (IV) delivery
          3. Others
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.